Skip to content

Plasma gene methylation detection and its combined conventional marker (G17/PGI/PGII/Hp) detection are used before the early diagnosis of gastric cancer Spectacular, case-control studies

Plasma gene methylation detection and its combined conventional marker (G17/PGI/PGII/Hp) detection are used before the early diagnosis of gastric cancer Spectacular, case-control studies

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300068695
Enrollment
Unknown
Registered
2023-02-27
Start date
2023-03-01
Completion date
Unknown
Last updated
2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early diagnosis of gastric cancer

Interventions

Index test:1. Plasma gene methylation detection 2. Gastrin 17, pepsin I/II, Helicobacter pylori Hp

Sponsors

Nanjing Gulou Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 84 Years

Inclusion criteria

Inclusion criteria: 1. Fully competent, 35~84 years old, regardless of gender. 2. Have or will have gastroscopy and/or pathological examination results at the Centre and agree to provide blood samples.

Exclusion criteria

Exclusion criteria: 1. I have a history of gastric cancer surgery/chemotherapy/radiotherapy. 2. Are pregnant or breastfeeding. 3. Those with severe intellectual disability or language communication impairment, severe heart, brain, lung disease or liver and kidney dysfunction. 4. Have taken demethylating drugs (such as decitabine, azacitidine, hydralazine, procainamide, Procaine, curcumin, etc.). 5. Are receiving or have received radiotherapy, chemotherapy, immunotherapy, or taking antineoplastic drugs (eg, epirubicin, carboplatin, paclitaxel, cisplatin, fluorouracil, capecitabine, tigio, trastuzumab, etc.).

Design outcomes

Primary

MeasureTime frame
Plasma gene methylation;sensitivity;Specificity;accuracy;Kappa consistency;

Countries

China

Contacts

Public ContactXiaoping Zou

Nanjing Gulou Hospital

13770771661@163.com13770771661

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026